STAT+: Sen. Cassidy wants to put a stop to FDA delays in drug review process
Sen. Bill Cassidy is concerned about the extended deadlines that can delay the FDA’s process for reviewing new drugs.
WASHINGTON — Sen. Bill Cassidy (R-La.) is looking into ways to speed up the Food and Drug Administration’s process for reviewing new drugs.
“We’re at the reallllly early stages, like ‘can we talk about it?’ sort of thing,” the ranking Senate health committee Republican said about his potential interest in putting a stop to the FDA’s tactic for extending drug review deadlines.
At issue are the product review deadlines that the FDA must meet in return for receiving industry user fees. The industries that the FDA regulates fund more than 45% of the agency’s budget.
What's Your Reaction?
